- About us
- Clinical trials
- News & Publications
SOTIO® is developing the next generation of potent immunotherapies for patients
SOTIO’s robust clinical pipeline includes a differentiated superagonist of the attractive immuno-oncology target IL-15, a proprietary technology designed to improve on the efficacy of CAR T therapies, a platform to streamline and enhance personalized cell therapies and a new generation of potent and stable antibody-drug conjugates.
SOTIO® is focused on advancing safer
and more effective immunotherapies
through clinical development.
SOTIO, a clinical stage immune-oncology company owned by PPF Group, today announced the presentation of positive biomarker data from its Phase 2 trial with dendritic cell vaccine DCVAC/OvCa during ...
SOT101 (formerly SO-C101) is an IL-15 superagonist that has been precisely designed and optimized for its use as a potent immunotherapy. It is currently being studied in an ongoing Phase 1/1b study …
SOTIO’s BOXR cell therapy platform is designed to improve the functionality of engineered T cells by identifying novel “bolt-on” transgenes that can be co-expressed with tumor-targeting receptors to overcome resistance and improve the function of T cells in the solid tumor microenvironment.